Jianming Ying

List of Publications by Year
in descending order

128 papers	2,892 citations	186209 28 h-index	214721 47 g-index
137 all docs	137 docs citations	137 times ranked	4532 citing authors

#	Article	IF	Citations
1	Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. Journal of Thoracic Oncology, 2020, 15, 816-826.	0.5	272
2	Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer?. European Radiology, 2018, 28, 2058-2067.	2.3	177
3	Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma. Clinical Cancer Research, 2021, 27, 43-51.	3.2	125
4	Multiregion Sequencing Reveals the Genetic Heterogeneity and Evolutionary History of Osteosarcoma and Matched Pulmonary Metastases. Cancer Research, 2019, 79, 7-20.	0.4	113
5	A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway. Oncotarget, 2015, 6, 31927-31943.	0.8	98
6	Transdifferentiation of tumor infiltrating innate lymphoid cells during progression of colorectal cancer. Cell Research, 2020, 30, 610-622.	5.7	91
7	Detection of ROS1 Gene Rearrangement in Lung Adenocarcinoma: Comparison of IHC, FISH and Real-Time RT-PCR. PLoS ONE, 2015, 10, e0120422.	1.1	87
8	EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study. Lung Cancer, 2020, 145, 186-194.	0.9	68
9	Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib. Lung Cancer, 2018, 118, 1-5.	0.9	63
10	Self‐Assembled Nanomedicines for Anticancer and Antibacterial Applications. Advanced Healthcare Materials, 2018, 7, e1800670.	3.9	63
11	Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC. Journal of Thoracic Oncology, 2021, 16, 404-418.	0.5	63
12	PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker. SpringerPlus, 2016, 5, 805.	1.2	61
13	P53-R273H mutation enhances colorectal cancer stemness through regulating specific lncRNAs. Journal of Experimental and Clinical Cancer Research, 2019, 38, 379.	3.5	59
14	Intergenic Breakpoints Identified by DNA Sequencing Confound Targetable Kinase Fusion Detection in NSCLC. Journal of Thoracic Oncology, 2020, 15, 1223-1231.	0.5	59
15	The efficiency of 18F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1209-1219.	3.3	56
16	Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next‐generation sequencing. Histopathology, 2019, 75, 890-899.	1.6	55
17	Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies. British Journal of Haematology, 2007, 136, 829-832.	1.2	52
18	Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter Phase 2 Study. Journal of Thoracic Oncology, 2016, 11, 910-917.	0.5	51

#	Article	IF	Citations
19	Response to crizotinib in advanced ALK -rearranged non-small cell lung cancers with different ALK -fusion variants. Lung Cancer, 2018, 118, 128-133.	0.9	50
20	Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer. Journal of Immunotherapy, 2019, 42, 215-220.	1.2	47
21	Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic EventsÂin ALK Fusion Patterns in NSCLC that RespondsÂto Crizotinib Treatment. Journal of Thoracic Oncology, 2017, 12, 94-101.	0.5	44
22	Concurrence of EGFR amplification and sensitizing mutations indicate a better survival benefit from EGFR-TKI therapy in lung adenocarcinoma patients. Lung Cancer, 2015, 89, 337-342.	0.9	43
23	Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment. Cancer Letters, 2018, 423, 9-15.	3.2	38
24	Changes in Expression of Multiple Checkpoint Molecules and Infiltration of Tumor Immune Cells after Neoadjuvant Chemotherapy in Gastric Cancer. Journal of Cancer, 2019, 10, 2754-2763.	1.2	38
25	Major challenges related to tumor biological characteristics in accurate mutation detection of colorectal cancer by next-generation sequencing. Cancer Letters, 2017, 410, 92-99.	3.2	35
26	Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Nonâ€"Small Cell Lung Cancer. JAMA Network Open, 2020, 3, e2013770.	2.8	34
27	A CLDN1-Negative Phenotype Predicts Poor Prognosis in Triple-Negative Breast Cancer. PLoS ONE, 2014, 9, e112765.	1.1	33
28	Epigenomic characterization of a p53-regulated 3p22.2 tumor suppressor that inhibits STAT3 phosphorylation via protein docking and is frequently methylated in esophageal and other carcinomas. Theranostics, 2018, 8, 61-77.	4.6	33
29	PIK3CA Gene Mutations and Overexpression: Implications for Prognostic Biomarker and Therapeutic Target in Chinese Esophageal Squamous Cell Carcinoma. PLoS ONE, 2014, 9, e103021.	1.1	30
30	PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population. Diagnostic Pathology, 2019, 14, 6.	0.9	30
31	Concomitant <i>TP53</i> mutations with response to crizotinib treatment in patients with <i>ALK</i>â€rearranged nonâ€smallâ€cell lung cancer. Cancer Medicine, 2019, 8, 1551-1557.	1.3	30
32	Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma. Nature Communications, 2020, 11, 4878.	5.8	27
33	Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodes. Npj Precision Oncology, 2020, 4, 32.	2.3	27
34	Clinicopathological features and surgical outcomes of four rare subtypes of primary liver carcinoma. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 364-372.	0.7	26
35	Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on B cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma. Cancer Immunology, Immunotherapy, 2022, 71, 2341-2354.	2.0	26
36	High frequency of clonal IG and T-cell receptor gene rearrangements in histiocytic and dendritic cell neoplasms. Oncotarget, 2016, 7, 78355-78362.	0.8	24

#	Article	IF	Citations
37	RC48-ADC for metastatic urothelial carcinoma with HER2-positive: Combined analysis of RC48-C005 and RC48-C009 trials.. Journal of Clinical Oncology, 2022, 40, 4520-4520.	0.8	23
38	The 3p14.2 tumour suppressor <scp>ADAMTS</scp>9 is inactivated by promoter CpG methylation and inhibits tumour cell growth in breast cancer. Journal of Cellular and Molecular Medicine, 2018, 22, 1257-1271.	1.6	22
39	Clinicopathologic Correlation With Expression of PD-L1 on Both Tumor Cells and Tumor-infiltrating Immune Cells in Patients With Non–Small Cell Lung Cancer. Journal of Immunotherapy, 2019, 42, 23-28.	1.2	22
40	Whole exome sequencing (WES) analysis of transformed small cell lung cancer (SCLC) from lung adenocarcinoma (LUAD). Translational Lung Cancer Research, 2020, 9, 2428-2439.	1.3	21
41	Subjecting appropriate lung adenocarcinoma samples to next‐generation sequencing‐based molecular testing: challenges and possible solutions. Molecular Oncology, 2018, 12, 677-689.	2.1	20
42	Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions. Genome Biology, 2021, 22, 109.	3.8	20
43	Prevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung Adenocarcinoma. PLoS ONE, 2015, 10, e0130447.	1.1	19
44	Genome wide copy number analyses of superficial esophageal squamous cell carcinoma with and without metastasis. Oncotarget, 2017, 8, 5069-5080.	0.8	18
45	Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer. Oncotarget, 2016, 7, 8332-8340.	0.8	18
46	Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade. Npj Precision Oncology, 2022, 6, 2.	2.3	17
47	Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology. Cancer Biology and Medicine, 2019, 16, 189.	1.4	16
48	Crizotinib vs platinum‐based chemotherapy as first‐line treatment for advanced non‐small cell lung cancer with different <i>ROS1</i> fusion variants. Cancer Medicine, 2020, 9, 3328-3336.	1.3	16
49	An open-label, single-arm, multicenter, phase II study of RC48-ADC to evaluate the efficacy and safety of subjects with HER2 overexpressing locally advanced or metastatic urothelial cancer (RC48-C009).. Journal of Clinical Oncology, 2021, 39, 4584-4584.	0.8	16
50	MET overexpression, gene amplification and relevant clinicopathological features in gastric adenocarcinoma. Oncotarget, 2017, 8, 10264-10273.	0.8	16
51	Identification of MET exon14 skipping by targeted DNA- and RNA-based next-generation sequencing in pulmonary sarcomatoid carcinomas. Lung Cancer, 2018, 122, 113-119.	0.9	14
52	Distinct clinical phenotype and genetic testing strategy for Lynch syndrome in China based on a large colorectal cancer cohort. International Journal of Cancer, 2020, 146, 3077-3086.	2.3	14
53	Detection of EGFR and KRAS gene mutations using suspension liquid-based cytology specimens in metastatic lung adenocarcinoma. Oncotarget, 2017, 8, 106685-106692.	0.8	13
54	Prevalence and characteristics of <i>PIK3CA</i> mutation in mismatch repair-deficient colorectal cancer. Journal of Cancer, 2020, 11, 3827-3833.	1.2	12

#	Article	IF	Citations
55	Clinicopathologic characteristics and diagnostic methods of RET rearrangement in Chinese non-small cell lung cancer patients. Translational Lung Cancer Research, 2022, 11, 617-631.	1.3	12
56	Distinct MET Protein Localization Associated With MET Exon 14 Mutation Types in Patients With Non–small-cell Lung Cancer. Clinical Lung Cancer, 2018, 19, e391-e398.	1.1	11
57	Classic SRY–box protein SOX7 functions as a tumor suppressor regulating WNT signaling and is methylated in renal cell carcinoma. FASEB Journal, 2019, 33, 254-263.	0.2	11
58	HER2 expression and relevant clinicopathological features in esophageal squamous cell carcinoma in a Chinese population. Diagnostic Pathology, 2020, 15, 27.	0.9	11
59	ALK Rearrangement–Positive Pancreatic Cancer with Brain Metastasis Has Remarkable Response to ALK Inhibitors: A Case Report. Frontiers in Oncology, 2021, 11, 724815.	1.3	11
60	Clinical significance of PCDH10 promoter methylation in diffuse large B-cell lymphoma. BMC Cancer, 2017, 17, 815.	1.1	10
61	PDCD6 cooperates with C-Raf to facilitate colorectal cancer progression via Raf/MEK/ERK activation. Journal of Experimental and Clinical Cancer Research, 2020, 39, 147.	3.5	10
62	Identification of DNA methylation biomarkers for risk of liver metastasis in early-stage colorectal cancer. Clinical Epigenetics, 2021, 13, 126.	1.8	10
63	Efficacy and safety of neoadjuvant PD-1 blockade with sintilimab in resectable squamous non-small cell lung cancer (sqNSCLC).. Journal of Clinical Oncology, 2019, 37, 8531-8531.	0.8	10
64	C-MYC overexpression predicts aggressive transformation and a poor outcome in mucosa-associated lymphoid tissue lymphomas. International Journal of Clinical and Experimental Pathology, 2014, 7, 5634-44.	0.5	10
65	Reliability analysis of exonic-breakpoint fusions identified by DNA sequencing for predicting the efficacy of targeted therapy in non-small cell lung cancer. BMC Medicine, 2022, 20, 160.	2.3	10
66	Development and external validation of a nomogram to predict four or more positive nodes in breast cancer patients with one to three positive sentinel lymph nodes. Breast, 2020, 53, 143-151.	0.9	9
67	Heterogeneous Response to First-Generation Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers with Different EGFR Exon 19 Mutations. Targeted Oncology, 2020, 15, 357-364.	1.7	9
68	High <scp>MAF</scp> of <scp><i>EGFR</i></scp> mutations and high ratio of <scp>T790M sensitizing mutations</scp> in <scp>ctDNA</scp> predict better third–generation <scp>TKI</scp> outcomes. Thoracic Cancer, 2020, 11, 1503-1511.	0.8	9
69	Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations. Thoracic Cancer, 2021, 12, 2924-2932.	0.8	9
70	Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer. Oncotarget, 2016, 7, 52862-52869.	0.8	9
71	Sequencing a super multiple synchronous lung cancer reveals a novel variant in driver gene ARID1B. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, e185-e191.	0.4	8
72	NGS-based oncogenic mutations analysis in advanced colorectal cancer patients improves targeted therapy prediction. Pathology Research and Practice, 2019, 215, 483-489.	1.0	8

#	ARTICLE	IF	CITATIONS
73	CRISPR Cas9-Mediated Selective Isothermal Amplification for Sensitive Detection of Rare Mutant Alleles. Clinical Chemistry, 2021, 67, 1569-1571.	1.5	8
74	Homogeneity and High Concordance of ALK Translocation in Primary Lung Adenocarcinoma and Paired Lymph Node Metastasis. Scientific Reports, 2017, 7, 10961.	1.6	7
75	Major challenges in accurate mutation detection of multifocal lung adenocarcinoma by next-generation sequencing. Cancer Biology and Therapy, 2020, 21, 170-177.	1.5	7
76	Correlation between <scp>CXCR4</scp>, <scp>CXCR5</scp> and <scp>CCR7</scp> expression and survival outcomes in patients with clinical <scp>T1N0M0</scp> non‐small cell lung cancer. Thoracic Cancer, 2020, 11, 2955-2965.	0.8	7
77	Tumor-Associated Stromal Cellular Density as a Predictor of Recurrence and Mortality in Breast Cancer: Results from Ethnically Diverse Study Populations. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1397-1407.	1.1	7
78	Interpretation of specification for breast cancer screening, early diagnosis, and treatment management in Chinese women. Journal of the National Cancer Center, 2021, 1, 97-100.	3.0	7
79	Clinicopathological features and prognostic analysis of 247 small cell lung cancer with limited-stage after surgery. Human Pathology, 2021, 108, 84-92.	1.1	6
80	Clinicopathological features and prognostic implications of <scp>ASCL1</scp> expression in surgically resected small cell lung cancer. Thoracic Cancer, 2021, 12, 40-47.	0.8	6
81	Cytoplasmic MSH2 Related to Genomic Deletions in the MSH2/EPCAM Genes in Colorectal Cancer Patients With Suspected Lynch Syndrome. Frontiers in Oncology, 2021, 11, 627460.	1.3	6
82	High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma. Future Oncology, 2021, 17, 2893-2905.	1.1	6
83	Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer. Breast Cancer Research and Treatment, 2017, 166, 77-84.	1.1	5
84	The prognostic value of a Methylome-based Malignancy Density Scoring System to predict recurrence risk in early-stage Lung Adenocarcinoma. Theranostics, 2020, 10, 7635-7644.	4.6	5
85	Necrosis Is Not the Main Part of Immune-Related Pathologic Response to Neoadjuvant Immunotherapy in Squamous Cell Lung Cancer. Journal of Thoracic Oncology, 2021, 16, e7-e9.	0.5	5
86	Guidelines for clinical practice of ALK fusion detection in non-small-cell lung cancer: a proposal from the Chinese RATICAL study group. Journal of the National Cancer Center, 2021, 1, 123-131.	3.0	5
87	Novel genetic characteristics in low‐grade fetal adenocarcinoma of the lung. Thoracic Cancer, 2021, 12, 2789-2795.	0.8	5
88	Programmable endonuclease combined with isothermal polymerase amplification to selectively enrich for rare mutant allele fractions. Chinese Chemical Letters, 2022, 33, 4126-4132.	4.8	5
89	Serum alpha-fetoprotein as a predictive biomarker for tissue alpha-fetoprotein status and prognosis in patients with hepatocellular carcinoma. Translational Cancer Research, 2022, 11, 669-677.	0.4	5
90	<scp>ASCL1</scp> and <scp>DLL3</scp> expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the <scp>National Cancer Center of China</scp>. Thoracic Cancer, 2022, 13, 338-345.	0.8	5

#	Article	IF	Citations
91	Outcome of chemotherapy with or without targeted agents in metastatic colorectal cancer patients with deficient DNA mismatch repair: A single center, cohort study. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 128-135.	0.7	4
92	Clinical significance of â‰¥ 50% PDâ€‑L1 expression with the SP263 monoclonal antibody in nonâ€small cell lung cancer patients. Thoracic Cancer, 2019, 10, 175-182.	0.8	4
93	Conjoint Analysis of DNA Methylation for Tumor Differentiation Using Cationic Conjugated Polymers. ACS Applied Bio Materials, 2020, 3, 2867-2872.	2.3	4
94	A modified screening strategy for Lynch syndrome among MLH1-deficient CRCs: Analysis from consecutive Chinese patients in a single center. Translational Oncology, 2021, 14, 101049.	1.7	4
95	Two-year follow-up of single PD-1 blockade in neoadjuvant resectable NSCLC.. Journal of Clinical Oncology, 2021, 39, 8522-8522.	0.8	4
96	Mutation Landscape of Homologous Recombination Repair Genes in Epithelial Ovarian Cancer in China and Its Relationship With Clinicopathlological Characteristics. Frontiers in Oncology, 2022, 12, 709645.	1.3	4
97	DrABC: deep learning accurately predicts germline pathogenic mutation status in breast cancer patients based on phenotype data. Genome Medicine, 2022, 14, 21.	3.6	4
98	Disease monitoring of epidermal growth factor receptor (EGFR)â€mutated nonâ€smallâ€cell lung cancer patients treated with tyrosine kinase inhibitors via <scp>EGFR</scp> status in circulating tumor <scp>DNA</scp>. Thoracic Cancer, 2022, 13, 2201-2209.	0.8	4
99	Genomic profile and immune microenvironment in patients with relapsed stage IA lung adenocarcinoma. Translational Oncology, 2021, 14, 100942.	1.7	3
100	Platform study of genotyping-guided precision medicine for rare solid tumours: a study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumours. BMJ Open, 2021, 11, e044543.	0.8	3
101	Comparing firstâ€line treatment patterns and clinical outcomes of patients with panâ€negative advanced nonâ€squamous nonâ€small cell lung cancer. Thoracic Cancer, 2018, 9, 1005-1011.	0.8	2
102	Concurrent Presence of ALK Rearrangement and MET Mutation in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2019, 14, e42-e44.	0.5	2
103	DLBCL with amplification of JAK2/PD-L2 exhibits PMBCL-like CNA pattern and worse clinical outcome resembling those with MYD88 L265P mutation. BMC Cancer, 2020, 20, 816.	1.1	2
104	The Reproducibility of Histopathologic Assessments of Programmed Cell Death-Ligand 1 Using Companion Diagnostics in NSCLC. JTO Clinical and Research Reports, 2021, 2, 100102.	0.6	2
105	Trends in Molecular Testing of Lung Cancer in Mainland Peopleâ€™s Republic of China Over the Decade 2010 to 2019. JTO Clinical and Research Reports, 2021, 2, 100163.	0.6	2
106	The Distinct Performances of Ultrasound, Mammograms, and MRI in Detecting Breast Cancer in Patients With Germline Pathogenic Variants in Cancer Predisposition Genes. Frontiers in Oncology, 2021, 11, 710156.	1.3	2
107	Sclerosing thymoma: a case report and literature review. Translational Cancer Research, 2020, 9, 3034-3039.	0.4	2
108	<scp>PSC</scp> subtyping based on <scp>TTF</scp>â€1 and p40 expression reveals distinct molecular characteristics and therapeutic strategies. International Journal of Cancer, 2022, 151, 717-729.	2.3	2

#	Article	IF	Citations
109	Evaluation of the fully automated Idylla EGFR Mutation Assay in Chinese patients with lung adenocarcinoma.. Journal of Clinical Oncology, 2020, 38, e21716-e21716.	0.8	1
110	Establishment and validation of a gasdermin signature to evaluate the immune status and direct risk‐group classification in luminal‐B breast cancer. Clinical and Translational Medicine, 2021, 11, e614.	1.7	1
111	Clinical significance of ALDH1A1 expression and its association with E-cadherin and N-cadherin in resected large cell neuroendocrine carcinoma. Translational Oncology, 2022, 19, 101379.	1.7	1
112	Assessment of a HER-2 scoring system and its correlation of HER2-targeting antibody-drug conjugate therapy in urothelial carcinoma.. Journal of Clinical Oncology, 2022, 40, 4572-4572.	0.8	1
113	Immune-related histologic phenotype in pretreatment tumor biopsy predicts pathologic response to neoadjuvant anti-PD-1 treatment in squamous lung cancer.. Journal of Clinical Oncology, 2021, 39, e20540-e20540.	0.8	0
114	Features in genomics and tumor immune microenvironment in NSCLC treated with neoadjuvant PD-1 blockade.. Journal of Clinical Oncology, 2021, 39, 9063-9063.	0.8	0
115	Metastatic NSCLCs With Limited Tissues: How to Effectively Identify Driver Alterations to Guide Targeted Therapy in Chinese Patients. JTO Clinical and Research Reports, 2021, 2, 100167.	0.6	0
116	EGFR mutation is positively correlated with C-Met protein expression: a study of 446 resected lung adenocarcinoma. Translational Cancer Research, 2021, 10, 233-240.	0.4	0
117	Multicenter study for the correlation among PD-L1 antibodies, tumor mutation burden (TMB) and lung immune prognostic index (lipi) in Chinese patients with advanced lung adenocarcinoma.. Journal of Clinical Oncology, 2018, 36, e21218-e21218.	0.8	0
118	Outcome of chemotherapy with or without targeted therapy in metastatic colorectal cancer with deficient mismatch repair phenotype: A cohort study in a single center.. Journal of Clinical Oncology, 2018, 36, e15669-e15669.	0.8	0
119	Effects of neoadjuvant chemotherapy on immune microenvironment and clinical outcomes in locally advanced gastric cancer.. Journal of Clinical Oncology, 2018, 36, e24133-e24133.	0.8	0
120	Effectiveness of crizotinib in a patient with mesenchymal-epithelial transition overexpression/fluorescence in situ hybridization-negative/next-generation sequencing-negative advanced lung adenocarcinoma: a case report. Translational Cancer Research, 2019, 8, 705-708.	0.4	0
121	Different expression and prognostic implications of PD-L1 in tumor cells and immune cells with the SP263 monoclonal antibody in Chinese urothelial carcinoma patients.. Journal of Clinical Oncology, 2019, 37, e16040-e16040.	0.8	0
122	DNA methylation signatures predicting liver metastasis of colorectal cancer: A proof-of-concept pilot study.. Journal of Clinical Oncology, 2020, 38, e16080-e16080.	0.8	0
123	Genomic and epigenomic profiles to distinguish pulmonary enteric adenocarcinoma from lung metastatic colorectal cancer.. Journal of Clinical Oncology, 2020, 38, e13528-e13528.	0.8	0
124	The Epidemic of Malignant Mesothelioma in China: A Prediction of Incidence During 2016-2030. SSRN Electronic Journal, 0, , .	0.4	0
125	A Pan-Cancer Analysis of the Oncogenic Role of WD Repeat Domain 74 in Multiple Tumors. Frontiers in Genetics, 2022, 13, 860940.	1.1	0
126	Analysis of non-sentinel lymph node status on 10-year overall survival among patients with breast cancer and sentinel lymph node metastasis.. Journal of Clinical Oncology, 2022, 40, e12584-e12584.	0.8	0

#	ARTICLE	IF	CITATIONS
127	Evaluation of the ability of Idylla EGFR to differentiate result of ARMS EGFR in gray area and identify rare mutation variants.. Journal of Clinical Oncology, 2022, 40, e15033-e15033.	0.8	0
128	Transcriptional analysis of small cell lung cancer transformation in epidermal growth factor receptor mutated lung adenocarcinomas.. Journal of Clinical Oncology, 2022, 40, e21100-e21100.	0.8	0